source
- Industry eyes revenue potential of next‑generation peptide drugs beyond GLP‑1The article notes that just a few years ago analysts were busy estimating the market size for GLP‑1 based weight‑loss medicines. Today the conversation has shifted toward the commercial possibilit…
- UK waitlist for Novo Nordisk’s Wegovy reaches 30,000 a week, tripling after approvalNovo Nordisk’s weight‑loss injection Wegovy has been approved in the United Kingdom. Within a week of the green light, a major online pharmacy reported that its waiting list surged to roughly 30,00…